Targets › GART
3 programs from 3 companies in 4 trials: 2 Phase 2, 2 Phase 1; Oncology; next expected readout Mar 2027.
Trifunctional enzyme that catalyzes three distinct reactions as part of the 'de novo' inosine monophosphate biosynthetic pathway. (UniProt, P22102)
Open in Phaseline: the race on GART, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Mayo Clinic | Pemetrexed Disodium Thymidylate synthase inhibitor; Dihydrofolate reductase inhibitor; GAR transformylase inhibitor | TYMS, DHFR, GART | Phase 2 | Metastatic Salivary Gland Carcinoma | Feb 2028 |
| NRG Oncology | Pemetrexed Disodium Thymidylate synthase inhibitor; Dihydrofolate reductase inhibitor; GAR transformylase inhibitor | TYMS, DHFR, GART | Phase 2 | Recurrent Non-Small Cell Lung Carcinoma | Dec 2028 |
| National Cancer Institute (NCI) | Pemetrexed Disodium Thymidylate synthase inhibitor; Dihydrofolate reductase inhibitor; GAR transformylase inhibitor | TYMS, DHFR, GART | Phase 1 | Epithelioid Mesothelioma; Biphasic Mesothelioma | Mar 2027 |
Recurrent Non-Small Cell Lung Carcinoma (1) Epithelioid Mesothelioma (1) Biphasic Mesothelioma (1) Metastatic Salivary Gland Carcinoma (1)
mixed (2), small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.